Loading…
Loading…
MDRSF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for MDRSF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MDRSF and 80,000+ other tickers.
See exactly how MDRSF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MDRSF and 80,000+ other tickers.
Medartis Holding AG is a Switzerland-based medical technology firm, founded in 1997 and headquartered in Basel. The company specializes in the global creation, production, and distribution of advanced implant solutions. These sophisticated medical devices are engineered to support the surgical repair and stabilization of bone fractures, specifically targeting injuries in both upper and lower limbs, as well as intricate cranio-maxillofacial surgeries. Operating under its prominent APTUS and MODUS brands, Medartis provides a comprehensive array of osteosynthesis instruments. These specialized…
Medartis Holding AG (MDRSF) Q2 2026 Press Conference Call Transcript
Medartis Holding AG (MDRSF) Discusses Strategy Roadmap and Innovation in Upper Extremities and Hand Products Transcript
Medartis Holding AG (OTCMKTS:MDRSF - Get Free Report) saw a significant decrease in short interest in February. As of February 27th, there was short interest totaling 115,820 shares, a decrease of 12.8% from the February 12th total of 132,888 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is currently ∞